ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 117 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,132,327 | -39.1% | 56,447 | -14.4% | 0.00% | -33.3% |
| Q2 2023 | $1,860,196 | +87.9% | 65,941 | +14.6% | 0.00% | +200.0% |
| Q1 2023 | $990,084 | -15.7% | 57,563 | -1.3% | 0.00% | -50.0% |
| Q4 2022 | $1,175,109 | -6.1% | 58,347 | +1.0% | 0.00% | 0.0% |
| Q3 2022 | $1,251,000 | -19.4% | 57,749 | +4.5% | 0.00% | 0.0% |
| Q2 2022 | $1,553,000 | -3.5% | 55,270 | +58.4% | 0.00% | 0.0% |
| Q1 2022 | $1,609,000 | -50.8% | 34,882 | -10.4% | 0.00% | -50.0% |
| Q4 2021 | $3,273,000 | +35.4% | 38,935 | +7.3% | 0.00% | +33.3% |
| Q3 2021 | $2,418,000 | -0.9% | 36,286 | -20.8% | 0.00% | 0.0% |
| Q2 2021 | $2,439,000 | +29.7% | 45,837 | +5.7% | 0.00% | +50.0% |
| Q1 2021 | $1,881,000 | -16.7% | 43,349 | -0.3% | 0.00% | -33.3% |
| Q4 2020 | $2,258,000 | +296.1% | 43,480 | +149.3% | 0.00% | +200.0% |
| Q3 2020 | $570,000 | -23.8% | 17,444 | +11.9% | 0.00% | 0.0% |
| Q2 2020 | $748,000 | – | 15,587 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Paradigm Biocapital Advisors LP | 300,434 | $25,254,000 | 7.21% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 | $220,944,000 | 6.56% |
| Avidity Partners Management LP | 2,715,000 | $228,223,000 | 4.84% |
| Matrix Capital Management Company, LP | 4,349,279 | $365,600,000 | 4.07% |
| Affinity Asset Advisors, LLC | 117,500 | $9,877,000 | 3.59% |
| Integral Health Asset Management, LLC | 120,000 | $10,087,000 | 2.79% |
| Ghost Tree Capital, LLC | 80,000 | $6,725,000 | 2.41% |
| Ikarian Capital, LLC | 191,140 | $16,067,000 | 2.39% |
| Tri Locum Partners LP | 23,632 | $1,987,000 | 0.78% |
| Eventide Asset Management | 529,000 | $44,468,000 | 0.57% |